- 2018-11-07
- Commercial Times: First in Taiwan! ACRO Biomedical's ABCcolla® Collagen Ophthalmic Matrix Approved for Human Clinical Trials
ACRO Biomedical, a company dedicated to human tissue engineering and regenerative medicine, obtained the license for human clinical trials on ABCcolla® Collagen Ophthalmic Matrix from the Department of Health and Welfare in Taiwan. The clinical trials will be conducted in Tri-Service General Hospital, Taipei Veterans General Hospital, Kaohsiung Veterans General Hospital, and Kaohsiung Medical University Chung-Ho Memorial Hospital.
The tissue regeneration technology of the collagen ophthalmic matrix has been published in an international journal and more than ten important seminars on ophthalmology. It has earned recognition from the ophthalmology experts. The approval for human clinical trials will bring great opportunities to the treatment for vision loss caused by acquired injury.
